GLP-1 use linked to lower rates of diabetic macular edema and glaucoma surgery
The analysis reported in AJMC adds ophthalmic outcomes to the growing list of secondary effects attributed to incretin therapy.
PR
By Priya Raman · Science Reporter
Oct 10 10:39 ETSource: The American Journal of Managed Care
The wire
- 01Researchers reported a protective association between GLP-1 receptor agonist use and diabetic macular edema as well as need for glaucoma surgery.
- 02Clinicians managing diabetic patients on semaglutide or tirzepatide may weigh ocular outcomes alongside metabolic endpoints when counseling.
- 03The report is observational; effect sizes, cohort size and confounding adjustments were not detailed, and causation cannot be inferred.
From the source
Read at ajmc.comGLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
